RPF2: A Potential Drug Target and Biomarker for Diseases (G84154)

Target Name: RPF2

NCBI ID: G84154

RPF2

RPF2: A Potential Drug Target and Biomarker for Diseases

RPF2 (BAA397G5.4), also known as BAP120, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the BAP family of proteins, which are known for their role in cell-cell adhesion and survival signaling. RPF2 has been identified as a potential drug target in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

RPF2 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is characterized by a N-terminal transmembrane domain, a cytoplasmic tail, and a singleton structure. The N-terminal transmembrane domain is known for its role in cell-cell adhesion and interaction, while the cytoplasmic tail is involved in the stability and localization of the protein. The singleton structure means that RPF2 is a monoclonal protein, which means that it is produced from a single gene.

RPF2 has been shown to play a role in various physiological processes in the body, including cell adhesion and signaling, as well as in the development and progression of various diseases. For example, RPF2 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In addition to its role in disease, RPF2 has also been identified as a potential drug target. Its unique structure and various functions make it an attractive target for small molecules, antibodies, and other therapeutic agents. Several studies have shown that RPF2 can be targeted by small molecules, such as inhibitors of its N-terminal transmembrane domain or its cytoplasmic tail. These small molecules have been shown to have various effects on RPF2, including the inhibition of its activity in cell adhesion and signaling.

In addition to its potential as a drug target, RPF2 has also been shown to be a valuable biomarker for various diseases. Its expression has been shown to be associated with various diseases, including neurodegenerative diseases, autoimmune disorders, and cancer. For example, RPF2 has been shown to be overexpressed in various neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be overexpressed in various autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

RPF2 has also been shown to have a role in the regulation of various cellular processes in the body. For example, it has been shown to be involved in the regulation of cell adhesion and migration, as well as in the regulation of ion channels and various signaling pathways. Its role in these processes makes it an important regulator of cellular behavior and growth.

In conclusion, RPF2 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and various functions make it an attractive target for small molecules, antibodies, and other therapeutic agents. Further research is needed to fully understand the role of RPF2 in various physiological processes in the body and its potential as a drug target and biomarker.

Protein Name: Ribosome Production Factor 2 Homolog

Functions: Involved in ribosomal large subunit assembly. May regulate the localization of the 5S RNP/5S ribonucleoprotein particle to the nucleolus

The "RPF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets